Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Budesonide Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

NCT01520688
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

NCT04600505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Jul 22, 2026, 5:31 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates

NCT03519061
View directory record Official record
Conditions
Chronic Sinus Infection, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinus Congestion
Interventions
Budesonide
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

NCT05444543
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone Propionate, Budesonide
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Comparison of Nasal Steroids After FESS in CRSwNP

NCT02194062
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
fluticasone nasal spray, Budesonide head upright, Budesonide head forward
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut • Stratford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

NCT00995904
View directory record Official record
Conditions
Asthma
Interventions
84ug MAP0020, 42ug MAP0020, 21ug MAP0020
Drug
Lead sponsor
Allergan
Industry
Eligibility
4 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

NCT06067828
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Tarzana, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 5:31 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

NCT07525375
View directory record Official record
Conditions
Asthma
Interventions
GP MDI, BFF MDI, Placebo MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 11 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Bakersfield, California • Long Beach, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

NCT01444430
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, budesonide pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
160
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012
View directory record Official record
Conditions
Asthma
Interventions
BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg, BD MDI 40 µg, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jul 22, 2026, 5:31 PM EDT
Terminated Phase 4 Interventional Results available

Budesonide in Patients With Immune Mediated Enteropathies

NCT03866538
View directory record Official record
Conditions
Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue, Autoimmune Enteropathy
Interventions
Withdrawal of Oral Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

NCT01642212
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (MB-9), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 40 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 22, 2026, 5:31 PM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 22, 2026, 5:31 PM EDT
Terminated Phase 4 Interventional Results available

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

NCT01070888
View directory record Official record
Conditions
Exercise Induced Asthma
Interventions
Budesonide/Formoterol, Budesonide
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

NCT07433569
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

NCT06268301
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Budesonide
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

NCT01453946
View directory record Official record
Conditions
Crohn's Disease
Interventions
Entocort
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Atlanta, Georgia • Oak Lawn, Illinois • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

NCT04032834
View directory record Official record
Conditions
Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tempe, Arizona • Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

NCT05755906
View directory record Official record
Conditions
Asthma
Interventions
BFF MDI 160/9.6 μg BID (320/19.2μg/day), BD MDI 160 μg BID (320 μg/day)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
63
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

NCT02605837
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (OBS), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 22, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Esophageal Clearance Times of Oral Budesonide Preparations

NCT02125851
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Xanthan Gum, Honey
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 22, 2026, 5:31 PM EDT